INCLUDED GENE THERAPY DRUGS

Embarc Benefit Protection®

EVERNORTH HEALTH SERVICES

FDA Approved	Therapy Name and Disease	Therapy Description	Contractual Limitations
2024	**Kebilidi™** Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency	Aims to correct the genetic cause of AADC deficiency, a rare nervous system disorder causing problems with motor control, muscle weakness, and delayed development	N/A
2024	**Beqvez™** Hemophilia B	Targets the patient's liver cells to produce their own factor, potentially reducing or eliminating the need for regular factor infusions	N/A
2024	**Lenmeldy™** Metachromatic leukodystrophy	For the treatment of a rare disease that affects the brains and nervous systems of children in their late infantile and early juvenile years	N/A
2023	**Lyfgenia™** Sickle cell disease	For the treatment of sickle cell disease (SCD) - an inherited blood disorder where red blood cells become hard, sticky, and shaped like a sickle. These misshapen cells block blood flow, causing pain, anemia, and organ damage. It's lifelong but manageable with treatment in patients 12 years and older with recurrent vaso-occlusive crises (VOCs)	For existing Embarc Benefit Protection clients with effective dates of April 1, 2024 or earlier, all customers who meet the solution's clinical and network criteria for Lyfgenia will be able to access the therapy through Embarc Benefit Protection. For clients who join Embarc Benefit Protection after April 1, 2024, the financial protection extends only to customers who join the underlying medical coverage 30 days or more after the client is effective in Embarc Benefit Protection.
2023	**Casgevy®** Sickle cell disease	For the treatment of sickle cell disease (SCD) - an inherited blood disorder where red blood cells become hard, sticky, and shaped like a sickle. These misshapen cells block blood flow, causing pain, anemia, and organ damage. It's lifelong but manageable with treatment in patients 12 years and older with recurrent vaso-occlusive crises (VOCs)	For existing Embarc Benefit Protection clients with effective dates of April 1, 2024 or earlier, all customers who meet the solution's clinical and network criteria for Casgevy (for the treatment of sickle cell disease) will be able to access the therapy through Embarc Benefit Protection. For clients who join Embarc Benefit Protection after April 1, 2024, the financial protection extends only to customers who join the underlying medical coverage 30 days or more after the client is effective in Embarc Benefit Protection.

THERAPY CLASSES

ONCOLOGY · CARDIOVASCULAR · HEMATOLOGY · RHEUMATOLOGY · TRANSPLANT · METABOLIC DISORDERS

DIABETES · OPHTHALMOLOGY · IMMUNOLOGY · DERMATOLOGY · NEUROLOGY · GENETIC DISORDERS

Last updated: July 2025

INCLUDED GENE THERAPY DRUGS

Embarc Benefit Protection®

EVERNORTH HEALTH SERVICES

2024		**Casgevy®** Beta-thalassemia	Used for a blood disorder known as beta-thalassemia in patients who cannot make enough beta-globin and require regular blood transfusions	N/A
2023		**Roctavian®** Hemophilia A	A gene therapy from BioMarin for the treatment of adults with severe Hemophilia A, with factor VIII activity less than 1 IU/dL, who are without pre-existing antibodies to adeno-associated virus serotype 5 (detected by an FDA-approved test)	N/A
2022		**Hemgenix®** Hemophilia B	For the treatment of adults with Hemophilia B (congenital Factor IX deficiency) who currently use Factor IX prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes	N/A
2022		**Skysona™** Adrenoleukodystrophy	To slow the progress of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD)	N/A
2022		**Zynteglo™** Beta-thalassemia	Used for a blood disorder known as beta-thalassemia in patients who cannot make enough beta-globin and require regular blood transfusions	N/A
2019		**Zolgensma®** Spinal Muscular Atrophy (SMA)	A gene therapy for children under two years of age with spinal muscular atrophy	The financial protection against the high cost of Zolgensma applies only to children born after the Embarc Benefit Protection solution is effective for their group health plan
2017		**Luxturna®** Retinal Dystrophy	The first FDA-approved prescription gene therapy for people with inherited retinal disease	N/A

THERAPY CLASSES

ONCOLOGY · CARDIOVASCULAR · HEMATOLOGY · RHEUMATOLOGY · TRANSPLANT · METABOLIC DISORDERS

DIABETES · OPHTHALMOLOGY · IMMUNOLOGY · DERMATOLOGY · NEUROLOGY · GENETIC DISORDERS

Last updated: July 2025